Enhancing Drug Discovery & Early Disease Detection
Novel chemiluminescence for superior detection of reactive oxygen, nitrogen, and sulfur species (RONSS) to propel critical therapies.
Our approach
Understanding the interplay between clinical and nonclinical research is crucial for gaining deeper insights into treatment utility and efficacy as early as possible. BioLum bridges this gap by redefining preclinical discovery and development models to accelerate much-needed therapies via a fully integrated R&D approach.
We prioritize early integration of sensitive & selective biomarker analysis, catalyzing the paradigm shift in precision medicine. Through robust partnerships with pharmaceutical developers, we’re uniquely positioned to unlock new mechanisms of action, novel targets, and transformational drug classes for better treatment and health outcomes.
Custom Services
BioLum excels in bioanalytical chemistry and custom assay development throughout the entire preclinical cycle, with a focus on chemiluminescent and fluorescent techniques. Drug discovery consists of multiple steps, centered on flexible, mutually beneficial collaborations. We work with partners to identify compound efficacy and understand mechanisms of action. Our custom services streamline development by facilitating rapid evaluation, quantitative insights, early target validation, dose dependency, drug interactions, in vitro analysis, and formula optimization. Along with this, we develop and synthesize small molecule probes (organic and inorganic) and custom assays according to specific client needs.
Chemiluminescence Kits
Our highly sensitive & selective assays for high-throughput screening (HTS) of fundamental biomarkers, significantly outperform existing gold standards (Griess & DAF). Our chemiluminescent formulas improve signal-to-noise by mitigating background autofluorescence, ensuring superior accuracy and precision. Available in buffered systems, plasma, serum, blood, and other sample media (living cells in progress).
In Vitro Diagnostics
Enable proactive, preventative health, our ultimate vision is to translate these kits from lab-based assays into standalone, point-of-care tests in the clinic. Our clinical tests will advance early diagnosis, patient stratification, and personalized treatment, empowering physicians and patients to better understand disease risks and conditions.
Disease Areas
-
Cardiovascular
-
Neurologic
-
Respiratory
-
Pain & Inflammation
“Tying the diagnostic and prognostic nature of markers into a companion diagnostic, or theragnostic is the ultimate goal.”
— James Januzzi, MD, Cardiac Biomarkers in Cardiovascular Clinical Trials: Caveats and Considerations
